Shares of CSL Limited (OTCMKTS:CSLLY) have received a consensus recommendation of “Hold” from the six analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company.
Several analysts have issued reports on CSLLY shares. Credit Suisse Group raised CSL from a “neutral” rating to an “outperform” rating in a research note on Tuesday, March 23rd. JPMorgan Chase & Co. lowered CSL from an “overweight” rating to a “neutral” rating in a research note on Wednesday, January 27th. Macquarie raised CSL from a “neutral” rating to an “outperform” rating in a research note on Tuesday. Zacks Investment Research lowered CSL from a “hold” rating to a “sell” rating in a research note on Tuesday, April 20th. Finally, The Goldman Sachs Group lowered CSL from a “buy” rating to a “neutral” rating in a research note on Thursday, February 18th.
Shares of CSLLY stock traded up $0.81 during trading on Tuesday, hitting $105.17. The company had a trading volume of 50,415 shares, compared to its average volume of 56,835. The company has a quick ratio of 1.37, a current ratio of 3.01 and a debt-to-equity ratio of 0.89. The stock’s 50-day moving average is $102.34 and its two-hundred day moving average is $106.41. The stock has a market capitalization of $95.73 billion, a price-to-earnings ratio of 45.53 and a beta of 0.59. CSL has a 52 week low of $91.04 and a 52 week high of $117.98.
CSL Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Featured Article: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.